| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 45.63% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 94.17% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $15.00 expecting OBIO to rise to within 12 months (a possible 45.63% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Piper Sandler, and Orchestra BioMed Hldgs initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a initiated with a price target of $0.00 to $15.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $10.30, which is within the analyst's predicted range.